*Our screening assessments for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) are currently undergoing validation with patient blood samples.
Resonant’s innovative approach detects cell-free DNA (cfDNA) from dying neurons with high sensitivity and specificity. We've developed a method that not only quantifies cfDNA concentrations in the blood but also identifies its cell-of-origin. This gives us a snapshot
of biomarkers of neurodegeneration from cortical, dopamine, and motor neurons.
Our panel is designed to equip physicians with early neurodgenerative insights to help patients make decisions that will preserve their quality of life the longest.
1: Gauthier, S., Rosa-Neto, P., Morais, J. A., & Webster, C. (2021). World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer’s Disease International, 2022, 30.
2: Segura, T., Medrano, I. H., Collazo, S., Maté, C., Sguera, C., Del Rio-Bermudez, C., ... & Taberna, M. (2023). Symptoms timeline and outcomes in amyotrophic lateral sclerosis using artificial intelligence. Scientific Reports, 13(1), 702.
3: Giguère, N., Burke Nanni, S., & Trudeau, L. E. (2018). On cell loss and selective vulnerability of neuronal populations in Parkinson's disease. Frontiers in neurology, 9, 383041.
